Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017–2019)
Objectives: The antimicrobial activity of tedizolid and comparators was evaluated against a large worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae isolates recovered from patients with pneumonia. Methods: Clinical isolates were collected from patients in 96 medical centres...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-06-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971221003258 |
| _version_ | 1818601298311774208 |
|---|---|
| author | Cecilia G. Carvalhaes Helio S. Sader Paul R. Rhomberg Rodrigo E. Mendes |
| author_facet | Cecilia G. Carvalhaes Helio S. Sader Paul R. Rhomberg Rodrigo E. Mendes |
| author_sort | Cecilia G. Carvalhaes |
| collection | DOAJ |
| description | Objectives: The antimicrobial activity of tedizolid and comparators was evaluated against a large worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae isolates recovered from patients with pneumonia. Methods: Clinical isolates were collected from patients in 96 medical centres in the Asia-Pacific region, Europe, Latin America and the USA between 2017 and 2019, and tested for susceptibility by reference broth microdilution. Results: The most active agents against S. aureus (n = 4667) were tedizolid (100.0% susceptible), linezolid (100.0% susceptible), ceftaroline (96.2% susceptible) and vancomycin (100.0% susceptible), but only tedizolid, linezolid and vancomycin retained activity against >95% of meticillin-resistant S. aureus isolates from all regions. In general, linezolid, ceftriaxone, ceftaroline, levofloxacin, penicillin and vancomycin showed susceptibility rates >95% against S. pneumoniae (n = 3008). However, only linezolid, ceftaroline, levofloxacin and vancomycin remained active (>95% susceptibility) against isolates displaying penicillin-non-susceptible or multidrug-resistant phenotypes. Penicillin-non-susceptible S. pneumoniae isolates were recovered less frequently from patients aged <5 years compared with other age groups. Conclusion: The in-vitro data presented here confirm the high potency of tedizolid against S. aureus and S. pneumoniae causing pneumonia worldwide. There is a need for further clinical evaluations of tedizolid for treating pneumonia caused by these pathogens. |
| first_indexed | 2024-12-16T12:49:09Z |
| format | Article |
| id | doaj.art-5767835ccdce4456a8c641299cbf2705 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-12-16T12:49:09Z |
| publishDate | 2021-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-5767835ccdce4456a8c641299cbf27052022-12-21T22:31:12ZengElsevierInternational Journal of Infectious Diseases1201-97122021-06-0110792100Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017–2019)Cecilia G. Carvalhaes0Helio S. Sader1Paul R. Rhomberg2Rodrigo E. Mendes3Corresponding author at: JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA.; JMI Laboratories, North Liberty, IA, USAJMI Laboratories, North Liberty, IA, USAJMI Laboratories, North Liberty, IA, USAJMI Laboratories, North Liberty, IA, USAObjectives: The antimicrobial activity of tedizolid and comparators was evaluated against a large worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae isolates recovered from patients with pneumonia. Methods: Clinical isolates were collected from patients in 96 medical centres in the Asia-Pacific region, Europe, Latin America and the USA between 2017 and 2019, and tested for susceptibility by reference broth microdilution. Results: The most active agents against S. aureus (n = 4667) were tedizolid (100.0% susceptible), linezolid (100.0% susceptible), ceftaroline (96.2% susceptible) and vancomycin (100.0% susceptible), but only tedizolid, linezolid and vancomycin retained activity against >95% of meticillin-resistant S. aureus isolates from all regions. In general, linezolid, ceftriaxone, ceftaroline, levofloxacin, penicillin and vancomycin showed susceptibility rates >95% against S. pneumoniae (n = 3008). However, only linezolid, ceftaroline, levofloxacin and vancomycin remained active (>95% susceptibility) against isolates displaying penicillin-non-susceptible or multidrug-resistant phenotypes. Penicillin-non-susceptible S. pneumoniae isolates were recovered less frequently from patients aged <5 years compared with other age groups. Conclusion: The in-vitro data presented here confirm the high potency of tedizolid against S. aureus and S. pneumoniae causing pneumonia worldwide. There is a need for further clinical evaluations of tedizolid for treating pneumonia caused by these pathogens.http://www.sciencedirect.com/science/article/pii/S1201971221003258MRSAPenicillin-non-susceptiblePneumococcusCAPOxazolidinone |
| spellingShingle | Cecilia G. Carvalhaes Helio S. Sader Paul R. Rhomberg Rodrigo E. Mendes Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017–2019) International Journal of Infectious Diseases MRSA Penicillin-non-susceptible Pneumococcus CAP Oxazolidinone |
| title | Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017–2019) |
| title_full | Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017–2019) |
| title_fullStr | Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017–2019) |
| title_full_unstemmed | Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017–2019) |
| title_short | Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017–2019) |
| title_sort | tedizolid activity against a multicentre worldwide collection of staphylococcus aureus and streptococcus pneumoniae recovered from patients with pneumonia 2017 2019 |
| topic | MRSA Penicillin-non-susceptible Pneumococcus CAP Oxazolidinone |
| url | http://www.sciencedirect.com/science/article/pii/S1201971221003258 |
| work_keys_str_mv | AT ceciliagcarvalhaes tedizolidactivityagainstamulticentreworldwidecollectionofstaphylococcusaureusandstreptococcuspneumoniaerecoveredfrompatientswithpneumonia20172019 AT heliossader tedizolidactivityagainstamulticentreworldwidecollectionofstaphylococcusaureusandstreptococcuspneumoniaerecoveredfrompatientswithpneumonia20172019 AT paulrrhomberg tedizolidactivityagainstamulticentreworldwidecollectionofstaphylococcusaureusandstreptococcuspneumoniaerecoveredfrompatientswithpneumonia20172019 AT rodrigoemendes tedizolidactivityagainstamulticentreworldwidecollectionofstaphylococcusaureusandstreptococcuspneumoniaerecoveredfrompatientswithpneumonia20172019 |